About Jacob Hooker

Jacob Hooker Wiki

Jacob Hooker, PhD, is CEO of Sensorium Therapeutics and a leading figure in neurochemistry and brain imaging.[11][16] With a PhD from UC Berkeley (2007) and prior roles at Harvard Medical School and MGH's Martinos Center, he pioneers PET radiotracers for CNS disorders.[1][4][10]

PET Radiotracer Development and Brain Imaging

Hooker's core expertise lies in designing radiotracers for positron emission tomography (PET) to visualize brain processes. He has advanced tools for imaging microglia in Parkinson's disease[6], epigenetic changes in Alzheimer's[17][19], and novel ligands like Radiocaine.[5] His philosophy for CNS radiotracer design emphasizes rapid synthesis and specificity.[4] At MGH, he used PET to explore brain inner workings and histone deacetylase inhibitors.[16][18]

Neurodegeneration and Mental Health Research

Hooker's work targets Parkinson's immune battles[6], Alzheimer's epigenetics[15][17], and psychiatric research via the Broad Institute.[15] As scientific director at the Lurie Center for Autism, he bridged imaging with neurodevelopmental disorders.[13] His mission at Sensorium Therapeutics focuses on transforming brain and mental health treatments.[11][23]

Chemistry of Consciousness and Altered States

Hooker explores psychoactive compounds, isolating salvinorin A from salvia to understand altered states.[14] This intersects with neuroscience, linking chemistry to mind mapping.[2][10]

Leadership, Trust, and Mindset

Beyond labs, Hooker champions trust as a 'performance multiplier' in professional settings.[7] He discusses coaching, mentorship, and mental health mindset shifts.[3][8] As CEO, he leads Sensorium's FDA-cleared SNTX-2643, a rapid-acting anxiolytic.[23]

Academic and Professional Milestones

PhD UC Berkeley, postdoc Brookhaven, Rappaport MGH Scholar (2016-2021).[4][13] Google Scholar highlights chemistry, PET, neuroscience.[1] Keynote speaker on brain science.[9]

Irrelevant news items (e.g., obituaries[20][21][22][24][25]) pertain to unrelated individuals.